9147 Bevacizumab and erlotinib as first-line therapy in advanced (stage IIIB/IV) non-squamous non-small-cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression – a multicenter phase II trial of SAKK

Francesco Zappa(Friedrich Schiller University Jena), Miklos Pless(Ontario Institute for Cancer Research), Daniel Rauch(Washington University in St. Louis), Roger von Moos(Kantonsspital Graubünden), Adrian F. Ochsenbein(University of Bern), Michael Mayer(Swiss Group For Clinical Cancer Research), Peter Schmid(St Bartholomew's Hospital), Daniel Betticher, R. Stahel, C. Droege(University Hospital of Basel)
European Journal of Cancer Supplements
September 1, 2009
10.1016/s1359-6349(09)71860-9
Cited by 3

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k